Fighting glioblastoma (GBM), one of the most aggressive and common brain tumors in adults, is a challenging task. Despite years of study, current treatments have failed to extend the survival of patients beyond 15 months. But Madan Kwatra, PhD (an associate professor of Duke’s Anesthesiology Department) and Glenn J. Lesser, MD, are hoping to add a new weapon to the therapeutic arsenal – a drug originally designed to fight lung cancer.
The National Center for Advancing Translational Sciences has awarded this Duke team with a “New Therapeutic Uses” project, providing them the opportunity to conduct further research over the next ten months. Pre-clinical studies will help determine whether this lung cancer drug can disrupt glioblastoma tumor growth in the brain.
In July, the NCATS awarded nearly $3 million to four academic research groups to test pharmaceutical industry assets and find new therapies for four specific diseases/conditions, including glioblastoma. Other awarded projects include Type 2 diabetes, acute myeloid leukemia and Chagas disease.
Read more at the Duke Translational Medicine Institute website.